Cite
Nabavi SM, Arab L, Jarooghi N, et al. Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial. Cell J. 2018;20(4):592-598doi: 10.22074/cellj.2019.5370.
Nabavi, S. M., Arab, L., Jarooghi, N., Bolurieh, T., Abbasi, F., Mardpour, S., Azimyian, V., Moeininia, F., Maroufizadeh, S., Sanjari, L., Hosseini, S. E., & Aghdami, N. (2019). Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial. Cell journal, 20(4), 592-598. https://doi.org/10.22074/cellj.2019.5370
Nabavi, Seyed Massood, et al. "Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial." Cell journal vol. 20,4 (2019): 592-598. doi: https://doi.org/10.22074/cellj.2019.5370
Nabavi SM, Arab L, Jarooghi N, Bolurieh T, Abbasi F, Mardpour S, Azimyian V, Moeininia F, Maroufizadeh S, Sanjari L, Hosseini SE, Aghdami N. Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial. Cell J. 2019 Jan;20(4):592-598. doi: 10.22074/cellj.2019.5370. Epub 2018 Aug 01. PMID: 30124008; PMCID: PMC6099146.
Copy
Download .nbib